A Phase l/ll Open-Label Study to Investigate the Safety Clinical Activity Pharmacokinetics and Pharmacodynamics of GSK3145095 Administered Alone and in Combination with Anticancer Agents Including Pembrolizumab in Adult Participants with Selected Advanced Solid Tumors
Brief description of study
This research study is being done to learn more about your cancer and the effects of GSK3145095. We also would like to answer the following questions: • Is GSK3145095 safe? • How well does GSK3145095 work to treat people with your cancer and related conditions? • What dose(s) of GSK3145095 works best? • How does your body break down GSK3145095? GSK3145095 is not approved by the US Food and Drug Administration (FDA). GSK3145095 will be administered to you via a pill you will swallow.
Clinical Study Identifier: s18-01225
ClinicalTrials.gov Identifier: NCTs18-01225
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
